Tracking Infections in Relapsed Myeloma Patients on Elranatamab
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study observes and records infections in adults with multiple myeloma that has returned or stopped responding to previous treatments, who are now being treated with a drug called elranatamab. The goal is to understand how often infections occur and help doctors manage them better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older (no upper age limit)
- You have relapsed or refractory multiple myeloma—meaning your cancer has come back or stopped responding to your most recent treatment within 60 days
- You have received at least three prior treatment regimens that included specific types of drugs: an immunomodulatory agent (like lenalidomide or pomalidomide), a proteasome inhibitor (like bortezomib or carfilzomib), and an anti-CD38 monoclonal antibody (like daratumumab or isatuximab)
- You are receiving elranatamab as part of your standard clinical care in Italy
- You are able and willing to provide written informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
This study tracks people with relapsed multiple myeloma who are taking elranatamab as part of their regular treatment. It will collect information about how well the medicine works and how safe it is.
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
This trial tests a new drug called elranatamab (given as an outpatient, not in the hospital) for people with multiple myeloma that has come back or stopped responding to several treatments. The goal is to see if taking it less often works well and is safer.
This trial tests whether giving letermovir (a medication to prevent CMV infection) is safe and effective for people with relapsed/refractory multiple myeloma who are starting elranatamab therapy. It is for patients who have already had several prior treatments and have been exposed to CMV in the past.
Hear when a new Multiple Mieloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.